View Older Stories View More Recent Stories

Oct 31, 2023 07:31AM Gilead Sciences' (GILD) Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
Oct 31, 2023 07:30AM Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
Oct 24, 2023 12:00PM Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
Oct 20, 2023 05:13AM Gilead Sciences (GILD) Presents New Data Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca
Oct 20, 2023 05:10AM New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
Oct 19, 2023 03:00AM Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
Oct 17, 2023 07:00AM Gilead Sciences (GILD) and Assembly Biosciences (ASMB) Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
Oct 17, 2023 07:00AM Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
Oct 16, 2023 01:01AM Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
Oct 12, 2023 04:05PM Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
Oct 3, 2023 08:30AM Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Oct 2, 2023 09:00AM Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
Sep 19, 2023 08:32AM Gilead Sciences (GILD) Announces CHMP Adopts Positive Opinion to Extend the Use of Veklury to Treat COVID-19 in People With Hepatic Impairment
Sep 19, 2023 08:30AM CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
Aug 24, 2023 08:30AM Gilead Sciences (GILD) Announces FDA Approval of Veklur to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Aug 24, 2023 08:30AM FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Aug 23, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Aug 21, 2023 08:30AM Gilead Sciences (GILD) Announces Partial Clinical Hold for Magrolimab Studies in AML
Aug 21, 2023 08:30AM Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
Aug 18, 2023 12:00PM Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
Aug 15, 2023 08:33AM Gilead Sciences (GILD) and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
Aug 15, 2023 08:30AM Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Aug 2, 2023 01:55PM Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Jul 27, 2023 01:29PM Gilead Sciences (GILD) Announces EU Approval of Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jul 27, 2023 01:23PM European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jul 25, 2023 05:39AM Gilead Sciences (GILD) Reports Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Jul 24, 2023 07:00PM Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Jul 24, 2023 06:07AM Gilead Sciences (GILD) To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Jul 23, 2023 09:51PM New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
Jul 23, 2023 05:00PM Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Jul 21, 2023 05:02PM Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Jul 20, 2023 12:00PM Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
Jul 19, 2023 08:30AM Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
Jul 14, 2023 04:05PM Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
Jul 14, 2023 08:03AM Gilead Sciences (GILD) Announces FDA Approval of Veklury for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Jul 14, 2023 08:00AM FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Jul 13, 2023 06:02AM Gilead Sciences (GILD) Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
Jul 13, 2023 06:00AM Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
Jun 23, 2023 08:12AM Gilead Sciences (GILD) Receives CHMP Positive Opinion for Trodelvy in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 23, 2023 08:11AM Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 23, 2023 02:30AM Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
Jun 15, 2023 04:01PM Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
Jun 14, 2023 03:00AM Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
Jun 6, 2023 10:47AM Gilead's(GILD) Kite's Tecartus CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate
Jun 6, 2023 10:45AM Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
Jun 5, 2023 12:34PM Gilead Sciences (GILD) Announces Trodelvy Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 5, 2023 12:30PM Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 5, 2023 11:25AM Gilead (GILD) Announces Kite’s Yescarta CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of R/R Large B-cell Lymphoma
Jun 5, 2023 11:25AM Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
View More Recent Stories View Older Stories